2023
Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.Peer-Reviewed Original Research
2022
Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics
Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.Peer-Reviewed Original ResearchConceptsLarge B-cell lymphomaDistinct clinicopathologic characteristicsMedian overall survivalB-cell lymphomaOverall survivalClinicopathologic characteristicsPrimary effusion lymphomaHHV8 infectionLymphomatous effusionsNon-germinal center B-cell subtypeLonger median overall survivalUnique clinicopathologic characteristicsFavorable prognostic factorEpstein-Barr virusSeparate diagnostic criteriaHuman herpesvirus 8B-cell subtypeMulti-institutional studyNon-Japanese casesDiagnostic uniformityImmunocompetent patientsPericardial effusionPericardial involvementSelect patientsChemotherapy administrationSafety considerations with the current treatments for peripheral T-cell lymphoma
Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPeripheral T-cell lymphomaT-cell lymphomaCombination chemotherapyTreatment regimensAnthracycline-based combination chemotherapyNK-T cell lymphomaB-cell non-Hodgkin lymphomaSingle-agent chemotherapyAvailable treatment regimensNon-Hodgkin lymphomaT cell subtypesSelection of agentsRelapsed settingAgent chemotherapyNatural killerFrontline treatmentPoor prognosisDisease groupUnique immunobiologyCurrent treatmentCell lymphomaCell disordersSide effectsLymphomaCertain complications
2021
Chemotherapy Knowledge Base Management in the Era of Precision Oncology.
Rubinstein SM, Sethi T, Venepalli NK, Gyawali B, Schwartz C, Rivera DR, Yang PC, Warner JL. Chemotherapy Knowledge Base Management in the Era of Precision Oncology. JCO Clinical Cancer Informatics 2021, 5: 30-35. PMID: 33411619, PMCID: PMC8189622, DOI: 10.1200/cci.20.00076.Peer-Reviewed Original ResearchHow we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCare
2020
Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside
Roy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal Of Leukocyte Biology 2020, 108: 1455-1489. PMID: 32557857, DOI: 10.1002/jlb.5bt0420-585rr.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMode of deliveryCancer vaccinesImmune checkpoint blockade agentsCheckpoint blockade agentsDifferent cancer vaccinesNeoantigen-based vaccinesRecent preclinical advancesCancer vaccine trialsCancer vaccine fieldLittle clinical activityPromising preclinical resultsMultiple cancer typesCheckpoint blockadeImmunotherapeutic trialsPreclinical advancesTherapeutic vaccinesVaccine trialsClinical activityPreclinical resultsClinical strategiesTherapeutic outcomesVaccine fieldClinical effortsVaccineCancer types
2019
Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma
Sethi TK, Kovach AE, Grover NS, Huang LC, Lee LA, Rubinstein SM, Wang Y, Morgan DS, Greer JP, Park SI, Thompson-Arildsen M, Yenamandra A, Vnencak-Jones CL, Reddy NM. Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma. Leukemia & Lymphoma 2019, 60: 2880-2889. PMID: 31184237, PMCID: PMC7280020, DOI: 10.1080/10428194.2019.1620942.Peer-Reviewed Original ResearchMeSH KeywordsAllelesAmino Acid SubstitutionBiomarkers, TumorCentral Nervous System NeoplasmsCombined Modality TherapyGenetic Association StudiesGenetic Predisposition to DiseaseHumansImmunohistochemistryIn Situ Hybridization, FluorescenceLymphocytes, Tumor-InfiltratingMacrophagesMutationMyeloid Differentiation Factor 88Neoplasm StagingPrognosisProgrammed Cell Death 1 ReceptorSignal TransductionSurvival AnalysisT-LymphocytesConceptsPD-1PD-L1Positive tumorsClinicopathologic correlatesT cellsPrimary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphomaPD-L1 positive tumorsEpstein-Barr virus infectionCentral nervous system lymphomaPotential targetable pathwayPD-L1 expressionProtein expressionNervous system lymphomaMyD88 protein expressionMYD88 L265P mutationSystemic lymphomaSystem lymphomaLymphoma patientsMacrophage infiltrationPoor prognosisVirus infectionTargetable pathwaysL265P mutationPathway alterations
2018
Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation
Aghighi M, Theruvath AJ, Pareek A, Pisani LL, Alford R, Muehe AM, Sethi TK, Holdsworth SJ, Hazard FK, Gratzinger D, Luna-Fineman S, Advani R, Spunt SL, Daldrup-Link HE. Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. Clinical Cancer Research 2018, 24: 4110-4118. PMID: 29764855, PMCID: PMC6125171, DOI: 10.1158/1078-0432.ccr-18-0673.Peer-Reviewed Original ResearchConceptsBone sarcomasClinical trialsFerumoxytol-enhanced MRIImmune-targeted therapiesProspective clinical trialsYoung adult patientsDensity of CD68Biopsy/resectionClin Cancer ResTumor biopsy/resectionInstitutional review boardNoninvasive imaging techniquesPrecontrast scansTAM densityAdult patientsPilot patientsPediatric patientsPostcontrast MRIPostcontrast scansCancer immunotherapyMacrophage stainingTumor responseMRI 24Tumor groupMalignant tumorsTreatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies
Sethi TK, Reddy NM. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Leukemia & Lymphoma 2018, 60: 6-18. PMID: 29741421, DOI: 10.1080/10428194.2018.1466296.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAge FactorsAgedAntineoplastic Combined Chemotherapy ProtocolsBiopsyBone MarrowBrainCentral Nervous System NeoplasmsChemoradiotherapyCognitive DysfunctionCranial IrradiationFemaleHumansLymphoma, Large B-Cell, DiffuseMagnetic Resonance ImagingMiddle AgedNeoplasm Recurrence, LocalPrognosisProgression-Free SurvivalRemission InductionStem Cell TransplantationTransplantation, AutologousConceptsPrimary central nervous lymphomaDiffuse large B-cell lymphoma histologyPrimary central nervous system lymphomaAutologous stem cell transplantCentral nervous system lymphomaMulti-agent chemotherapyNervous system lymphomaStem cell transplantNon-Hodgkin lymphomaLong-term toxicityEligible patientsImmunotherapy optionsRelapsed diseaseAggressive presentationUpfront therapySystem lymphomaCell transplantFrontline treatmentPathogenetic pathwaysLymphoma histologyCurrent evidenceFrontline strategyLymphomaTherapyOngoing studies
2017
Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis
Oke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, Concepcion B, Horst S, Jagasia M, Kassim A, Harrell SL, Langone A, Lenihan D, Rawling KT, Slosky D, Cornell RF. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. Transplantation And Cellular Therapy 2017, 23: 1473-1477. PMID: 28546074, DOI: 10.1016/j.bbmt.2017.05.020.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBortezomibFemaleHematopoietic Stem Cell TransplantationHumansImmunoglobulin Light-chain AmyloidosisInduction ChemotherapyMaleMiddle AgedMultivariate AnalysisNatriuretic Peptide, BrainProportional Hazards ModelsProteinuriaRetrospective StudiesStroke VolumeTransplantation, AutologousTreatment OutcomeConceptsAutologous hematopoietic cell transplantationProgression-free survivalTransplantation-related mortalityHematopoietic cell transplantationOverall survivalCT cohortLight chain amyloidosisCell transplantationLower brain natriuretic peptide levelsChain amyloidosisBrain natriuretic peptide levelsMedian progression-free survivalSuperior progression-free survivalBortezomib-based treatmentExperienced transplantation centersGood partial responseNatriuretic peptide levelsCohort of patientsMajority of patientsHigher ejection fractionEligible patientsInduction chemotherapyInduction therapyPartial responseEjection fractionBeyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies
Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Current Hematologic Malignancy Reports 2017, 12: 257-267. PMID: 28233150, DOI: 10.1007/s11899-017-0369-y.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCardiovascular side effectsHematologic malignanciesSide effectsUnique side effect profileCardiovascular adverse eventsSide effect profileLong-term administrationNon-Hodgkin lymphomaChronic myeloid leukemiaTyrosine kinase inhibitorsYears of ageOrgan-specific toxicityAdverse eventsFace of treatmentTargeted agentsEffect profilePatient populationCardiovascular toxicityMyeloid leukemiaNew agentsPreemptive managementMalignancyPrior exposureKinase inhibitorsProteasome inhibitors
2016
Beyond Epstein-Barr virus: genetic predisposition of natural killer T-cell lymphoma
Reddy NM, Sethi TK. Beyond Epstein-Barr virus: genetic predisposition of natural killer T-cell lymphoma. The Lancet Oncology 2016, 17: 1176-1177. PMID: 27470080, DOI: 10.1016/s1470-2045(16)30205-4.Commentaries, Editorials and LettersThree-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.
Aghighi M, Boe J, Rosenberg J, Von Eyben R, Gawande RS, Petit P, Sethi TK, Sharib J, Marina NM, DuBois SG, Daldrup-Link HE. Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. Radiology 2016, 280: 905-15. PMID: 26982677, PMCID: PMC5006736, DOI: 10.1148/radiol.2016151301.Peer-Reviewed Original ResearchConceptsBasis of RECISTWorld Health OrganizationTherapeutic responseStandard of referenceOverall survivalClinical outcomesTumor responseTumor measurementsThree-dimensional tumor measurementsResponse Evaluation CriteriaPrimary tumor sizeLog-rank testKaplan-Meier plotsTherapeutic response assessmentInstitutional review boardTumor volume measurementsVolume measurementsPatient survivalRetrospective studyCox regressionTumor sizeGroup criteriaBland-Altman analysisEwing's sarcomaMedical CenterHistology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas
Sethi TK, Keedy VL. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas. Current Treatment Options In Oncology 2016, 17: 11. PMID: 26931561, DOI: 10.1007/s11864-015-0382-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTyrosine kinase inhibitorsTreatment optionsEfficacy of TKIsMulti-targeted tyrosine kinase inhibitorAlveolar soft part sarcomaKinase inhibitorsNon-GIST sarcomasSpectrum of sarcomasFirst-line treatmentEfficacy of imatinibSoft tissue sarcomasImportant clinical questionsPoor response ratesSoft part sarcomaTarget-specific agentsDermatofibrosarcoma protruberansUnresectable diseaseAdvanced sarcomasRECIST criteriaBone sarcomasClinical efficacyTissue sarcomasRare tumorPreclinical dataChemotherapeutic options
2012
Radon and lung cancer.
Sethi TK, El-Ghamry MN, Kloecker GH. Radon and lung cancer. Clinical Advances In Hematology And Oncology 2012, 10: 157-64. PMID: 22402423.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLung cancerTobacco smokeSmoking cessation measuresIndependent risk factorLung cancer deathsCancer prevention effortsCancer-related deathCessation measuresMechanisms of carcinogenesisCancer deathRisk factorsNumerous cohortsCancerPrevention effortsRadon exposureCausative effectReactive oxygen speciesCarcinogenic potentialCommon mechanismDeathOxygen speciesDNA damageCauseRadon mitigationSmoke